YEAR EVENTS 1951 - The company was Incorporated on 1st May, as a private limited company under the name International Franchise Pvt. The Company manufacture drugs and pharmaceuticals, chemicals, cosmetics and toileteries. It started its activities with the manufacture of a brand of tooth paste and antiseptic lotion and extended them to the manufacture of pharmaceutical specialities of foreign companies on leave licence scheme. - DIL was promoted by Solvay Pharmaceuticals based Brussels and Mr. D. Vasant Kumar and family in India. 1962 - The Collaboration agreements were concluded with N.V. Philips - Duphar of Amsterdam and the Crookes Laboratories Ltd., London. The Company became a public limited company with effect from 9th April, 1963 and simultaneously its name was changed to Crookes Interfran Ltd. - The Company was entitled to obtain technical know-how for the manufacture of basic chemical, Vitamin `D' from N.V. Philips `Gloeilampenfabrieken, Holland. 1967 - The first phase of vitamin `D' manufacture was undertaken in May from imported resin. Import substitution was implemented in certain chemicals like neo-ferrum flakes, iodine concentrate and paracetamol. - 800 No. of equity share and 200 pref. shares issued by Feb. 1963. Around March 1963, 800 No. of equity shares issued at par to collaborators. Around Dec. 1964, 800 right equity shares issued at par in prop. 1:2 and pref. shares redeemed. In Sept. 1967, 1,200 No. of equity shares issued at par in prop. 1:2. In Sept. 1969, Rs 9 lakhs capitalised to make partly paid shares fully paid-up. 1971 - The name of the Company was changed to Duphar-Interfran Ltd. 1975 - The second phase was (irradiation) of vitamin `D' was implemented. The Company's products included `Crookes' transfusion, crocin and lacto-calamine, Duphar's research specialities of vasodilators and progrestational agents. - In Dec. 1970, shares subdivided. In Oct. 1975, 36,000 bonus shares issued in prop. 1:1. 1977 - On 24-12-1976, shares subdivided. During July 1977, 2,00,000 shares offered (prem. Rs 2.50 per share) to the public. 1979 - The Company undertook to set up a joint venture company under the name Fermentapharma Biodil Ltd., at Takoli village, Mandi district in Himachal Pradesh for the manufacture of basic drug intermediates used in the production of essential semi-synthetic antibiotics. 1984 - A modernisation and replacement to programme was taken up at the cost of Rs 100 lakhs. - 4,60,000 bonus equity shares issued in prop. 1:2. 1985 - Profitability was affected by a strike in the Vapi unit. The Vapi factory could not make adequate contribution to sales on account of low employee effectiveness. - The Company obtained registration for the manufacture of some bulk drugs and their formulations. 1988 - The Company privately placed with financial institutions 1,20,000-14% non-convertible debentures of Rs 100 each for Rs 120 lakhs. - 4,60,000 bonus shares issued in prop. 1:3. 1991 - 3,22,000 shares issued (prem. Rs 35 per share), 3.06,667 shares rights (prop. 1:6) and 15,333 shares to employees (all were taken up). Allotment was made on 1.6.1991. 1992 - The Company continued to concentrate towards development of new formulation, bulk drugs and intermediates in the field of synthetic and fermentation technology and in improving process of the existing formulation and bulk drugs. - The Company proposed to set up a third manufacturing unit at Takwe, Maharashtra for the commercial production of formulation. The company proposed to introduce Vitamin D3 combination for veterinary use. - The Company has developed chemical preparation of Sulbactam, a beta-lactamase inhibitor. Amoxycillin Dispersible Tablet was introduced in the market. - During the year the company's Pilot Plant was engaged in the scaling up of in-house processes developed by the company's R & D Division for the manufacture of 7-ADCA by enzymatic conversion of Ceph-G, jCephalexin and Sulbactam. Besides , locally developed technology for Cholorzoxazone was tried out in the Pilot Plant. - It is proposed to install Heat Recovery System and a high efficiency boiler at the Vapi Works. 1993 - The Company has undertaken expansion programme by recreating its Vitamin D3 plant at Thane. - Vitamin D3 preparation in Arachis Oil for Animal Feed was developed. The Company proposes to introduce Vitamin D3 combination for veterinary use. - During the year the company's Pilot Plant was engaged in the scaling up of in-house processes for Sulbactam and Chlorzoxazone. 1994 - The Company, proposed to issue 3,60,333 New Equity Shares of Rs. 10/- each as Rights Shares at a premium of Rs.45 per share. These shares will be offered to the Shareholders of the Company in the ratio of one such New Equity Share for every six existing shares held. - Two new bulk drugs namely Chlorzoxazone and Sulbactam Sodium which were developed through indigenously developed in-house technology have been successfully manufactured on commercial scale essentially for captive consumption. - Vitamin D3, liquid formulation for Animal Feed has been developed and is being launched in the market. 1995 - The Company offered 3,60,333 No. of equity shares of Rs 10 each at a premium of Rs 45 per share on rights basis to the existing shareholders in the ratio of 1:6. The number of shares offered was increased to 3,62,871 on account of rounding off of fractional entitlement. All were taken up. - The Company set up a third manufacturing unit at village Takwe (Budruk), Taluka - Maval, District - Pune. 1996 - The Company effected sale of its main product namely, "Crocin range" during the year since it was not giving the expected growth and yield and its contribution to profit was at a decreasing rate. - The Company has already launched in February one of the Gynaec products under the brand name "Yutopar". The other new products in the pipeline are Luvox, a psychotropic product. - The Company introduced Voluntary Retirement Scheme for its workmen and staff members at Thane Factory and Head Office. 1997 - During the year, the Company launched a new product under the brand name UDILIV for chronic hepatitis, cholestasis and dissolution of gall stones indications. - The Company has an R & D Laboratory approved by DSIR for chemicals and pharmaceutical research and development activity. - A wage settlement was signed with Unions of Medical Representatives. Similarly, a wage agreement with the Union of Thane and H.O. Workmen and Staff was also signed. 1998 - Duphar-Interfran is present in categories like antibiotics, anti-stress therapy, iodine therapy and muscle spasm. Some of its well-known brands include Moxydil, Ginsec and Duodil tablets. - Duphar is also planning to launch new formulations in various categories. - The company's R&D laboratory is now trying to develop and market new animal-feed supplement containing vitamins and minerals. - Duphar-Interfran also plans to launch formulations in various categories. The company launched a product under the brand name Udiliv for chronic hepatitis, cholestasis and dissolution of gall stones indications. 1999 - The Company has DSIR approved R&D Centre. During the year, research programme for finding out new lead molecules of medicinal importance and development of indigenous technologies for major drugs and intermediates were continued. - Electrical capacitors of sufficient size were installed at main electrical distribution and at key motor control panels by which the power factor was maintained at the efficient level resulting in considerable power saving. - The Company has an extensive computer network. 2000 - Duphar-Interfran Ltd (DIL) has said it is demerging its pharmaceutical business into a new company. - The Company has signed agreements with NSDL and CDSL for dematerialisation of the company's shares and for electronic connectivity. 2002-Duphar-Interfran Ltd has informed that Mr Kunal Kashyap has been appointed as a Director on the Board of the company. 2005 -Registered Office of the Company has been shifted From Worli, Mumbai to Thane 2007 - Dil Ltd has appointed Mr. Sanjay Buch as an additional director (Independent Category) with effect from April 28, 2007. 2008 -Dil Ltd has recommended an equity dividend of 100% 2009 -Dil Ltd has declared Interim Dividend & recommended Final Dividend of Rs 7.50 per share respectively. 2010 -Dil Ltd has recommended final equity dividend @ Rs. 7.50/- per equity share -Dil Ltd has declared Interim Dividend @ Rs. 7.50/- per equity share 2011 -Dil Ltd has recommended final equity dividend @ Rs. 10/- per equity share -Dil Ltd has declared interim equity dividend @ Rs. 15/- per equity share 2012 -Dil Ltd has recommended final equity dividend @ Rs. 15/- per equity share -Dil Ltd has declared interim equity dividend @ Rs. 15/- per equity share 2013 -Dil Ltd has signed "Agreement with Advertising Agents and Consultants". 2014 -Board has been appointed Dr. Gopakumar Nair as an Additional Director of the company. 2016 -Dil Ltd has informed the shifting of registered office of the Company from "DIL Complex, Ghodbunder Road, Majiwada, Thane (West) - 400 610, Maharashtra, India" to "A -1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (West) 400 610, Maharashtra, India". 2018 -The Company has issued Bonus Shares in the Ratio of 1:1. 2019 -Company name has changed to Fermenta Biotech Ltd. from DIL Ltd. 2020 -The Company has issued Bonus Shares in the Ratio of 2:1. 2021 -Fermenta received the prestigious Maharashtra Industrial and Economic Development Association presented Pride of Maharashtra Awards 2021 as the Best Company of the Year for Excellence in Exports. -Fermenta was awarded as the runner up in the category "Excellence in R&D" for the Development of new Product/ technology in India Pharma Awards 2021. 2023 -Fermenta with the "Excellence in Logistics Performance - Pharma Award", presented at the 5th India Logistics and Warehousing Excellence Awards 2023.